Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment-Reference-Cited by-同舟云学术

Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment

Published:2020-09-24 Issue:5 Volume:21 Page:1001-1010
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Genuino Anne Julienne¹,Gloria Mac Ardy Junio¹²,Chaikledkaew Usa¹³,Reungwetwattana Thanyanan⁴,Thakkinstian Ammarin¹⁵

Affiliation:

1. Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand

2. Department of Pharmacy, College of Pharmacy, University of the Philippines Manila, Manila, The Philippines

3. Social and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand

4. Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

5. Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2020.1819795

Reference56 articles.

1. Cancer WHO-IAfRo. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 [web page]. World Health Organization; 2012 [cited 2017]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx

2. World Health Organization. GLOBOCAN 2008: cancer incidence and mortality worldwide. World Health Organization, Geneva; 2010.

3. Cancer survival in five continents: a worldwide population-based study (CONCORD)

4. World Health Organization. Breast cancer: prevention and control. World Health Organization, Geneva; 2017.

5. The reality of economics for oncologists

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis;PLOS ONE;2024-05-24

2. Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review;Expert Review of Pharmacoeconomics & Outcomes Research;2024-05-20

3. Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam;PLOS ONE;2024-03-15

4. Anti-HER2 therapy response assessment for guiding treatment (de-)escalation in early HER2-positive breast cancer using a novel deep learning radiomics model;European Radiology;2024-02-08

5. Breast cancer methodology for maximization of resources currently used in Mexican centers;Gaceta Mexicana de Oncolog�a;2023-10-30